Exiqon A/S and Oncotech Inc today announce that they have entered into a
binding Letter of Intent under which Exiqon will acquire Oncotech, a California
based leading supplier of extreme drug resistance diagnostic tests in cancer.
The transaction will create a world leader in molecular diagnostic products
based on miRNA. The consideration amounts to approximately USD 45 million
(approximately DKK 225 million) and will be paid through to approx. 6,2 million
newly issued shares in Exiqon A/S as of November 26, 2007.
